4-[-4-(tetrahydro-pyran-4-yl)-phenyl]-morpholin-3-one | 872882-92-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 4-[-4-(tetrahydro-pyran-4-yl)-phenyl]-morpholin-3-one
• 英文别名: 4-[4-(Tetrahydro-pyran-4-yl)-phenyl]-morpholin-3-one；4-[4-(oxan-4-yl)phenyl]morpholin-3-one
• CAS: 872882-92-3
• 化学式: C₁₅H₁₉NO₃
• 分子量: 261.321
• InChiKey: COWAVNGIOFXHNG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-methylpiperazin-1-yl)nicotinaldehyde 、 4-[-4-(tetrahydro-pyran-4-yl)-phenyl]-morpholin-3-one 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 以56%的产率得到2-[2-(4-methylpiperazin-1-yl)pyridin-3-ylmethylene]-4-[4-(tetrahydropyran-4-yl)phenyl]morpholin-3-one
  参考文献：
  名称：

  Pyridyl piperazines for the treatment of CNS disorders

  摘要：

  这项发明涉及到式I化合物和包括式I化合物的药物组合物；其中虚线代表可选的双键；n为1或2，Ar1、Ar2等为规范中定义的化学基团。该发明还涉及一种治疗可以通过改变5-羟色胺介导的神经传递来治疗的疾病或症状的方法，如偏头痛、头痛、集群头痛、焦虑、抑郁等。该发明还涉及在合成式I化合物过程中有用的中间体。

  公开号：

  US20060025421A1
• 作为产物：
  描述：

  4-[4-(Tetrahydro-pyran-4-yl)-phenyl]-morpholine 在 potassium permanganate 、 苄基三乙基氯化铵 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 以24%的产率得到4-[-4-(tetrahydro-pyran-4-yl)-phenyl]-morpholin-3-one
  参考文献：
  名称：

  Pyridyl piperazines for the treatment of CNS disorders

  摘要：

  这项发明涉及到式I化合物和包括式I化合物的药物组合物；其中虚线代表可选的双键；n为1或2，Ar1、Ar2等为规范中定义的化学基团。该发明还涉及一种治疗可以通过改变5-羟色胺介导的神经传递来治疗的疾病或症状的方法，如偏头痛、头痛、集群头痛、焦虑、抑郁等。该发明还涉及在合成式I化合物过程中有用的中间体。

  公开号：

  US20060025421A1

文献信息

• WO2006/106416
  申请人：——

  公开号：——

  公开（公告）日：——
• PYRIDYL PIPERAZINES FOR THE TREATMENT OF CNS DISORDERS
  申请人：Pfizer Products Inc.

  公开号：EP1768975A2

  公开（公告）日：2007-04-04
• [EN] PYRIDYL PIPERAZINES FOR THE TREATMENT OF CNS DISORDERS<br/>[FR] PYRIDYLE PIPÉRAZINES POUR LE TRAITEMENT DES TROUBLES DU SNC
  申请人：PFIZER PROD INC

  公开号：WO2006000912A2

  公开（公告）日：2006-01-05

  This invention is directed to compounds of Formula (I) and to pharmaceutical compositions comprising the compound of Formula (I) or a prodrug thereof and a pharmaceutically effective carrier. where G is G 1 or G2; where the dashed line represents an optional double bond; and where n is 1 or 2, and Ar1, Ar2, ... and Z are as defined in the specification. The invention is also directed to a method of treating or preventing in mammals, including humans, a disorder or condition that can be treated by altering serotonin-mediated neurotransmission, including a disorder selected from the group consisting of migraine, headache, cluster headache, anxiety, depression, dysthymia, major depressive disorder, migraine, post-traumatic stress disorder, avoidant personality disorder, borderline personality disorder and phobias This invention is also directed to intermediates useful in the synthesis of compounds of Formula (I).
• [EN] PYRIDIL-LACTAMS AND THEIR USE 5 -HTl RECEPTORS LIGAN<br/>[FR] PYRIDIL-LACTAMS ET LEUR UTILISATION COMME LIGANDS DE RECEPTEURS 5-HT1
  申请人：PFIZER PROD INC

  公开号：WO2006106416A1

  公开（公告）日：2006-10-12

  [EN] The present invention relates to novel pyridyl-lactams, compounds of the formula (I), wherein R¹ is a group of the formula G¹, G², G³ or G⁴ depicted below, and R³, Y, R⁶, R⁷, R⁸, R¹³, a, n and m are as defined herein, their pharmaceutically acceptable salts, pharmaceutical compositions, their preparation and intermediates therefrom, and their use in treating or preventing depression, anxiety, obsessive compulsive disorder (OCD) and other disorders for which a 5-HT_1B antagonist is indicated.
  [FR] L'invention concerne de nouveaux composés pyridil-lactams de la formule (I), dans laquelle R₁ est un groupe de la formule G¹, G², G³ ou G⁴ illustrée ci-dessous, et R³, Y, R⁶, R⁷, R⁸, R¹³, a, n et m sont tels que définis dans le descriptif, leurs sels pharmaceutiquement acceptables, des compositions pharmaceutiques, leur préparation et les intermédiaires associés, ainsi que leur utilisation dans le traitement ou la prévention de la dépression, de l'anxiété, du trouble obsessionnel compulsif (OCD) et d'autres troubles contre lesquels un antagoniste 5-HT_1B est indiqué.
• Pyridyl piperazines for the treatment of CNS disorders
  申请人：Brodney A. Michael

  公开号：US20060025421A1

  公开（公告）日：2006-02-02

  This invention is directed to compounds of Formula I and to pharmaceutical compositions comprising the compound of Formula I. where the dashed line represents an optional double bond; and where n is 1 or 2, and Ar 1 , Ar 2 , . . . and Z are as defined in the specification. The invention is also directed to a method of treating a disorder or condition that can be treated by altering serotonin-mediated neurotransmission, such as migraine, headache, cluster headache, anxiety, depression, etc. This invention is also directed to intermediates useful in the synthesis of compounds of Formula I.

  这项发明涉及到式I化合物和包括式I化合物的药物组合物；其中虚线代表可选的双键；n为1或2，Ar1、Ar2等为规范中定义的化学基团。该发明还涉及一种治疗可以通过改变5-羟色胺介导的神经传递来治疗的疾病或症状的方法，如偏头痛、头痛、集群头痛、焦虑、抑郁等。该发明还涉及在合成式I化合物过程中有用的中间体。